PE20020323A1 - COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) - Google Patents
COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)Info
- Publication number
- PE20020323A1 PE20020323A1 PE2001000826A PE2001000826A PE20020323A1 PE 20020323 A1 PE20020323 A1 PE 20020323A1 PE 2001000826 A PE2001000826 A PE 2001000826A PE 2001000826 A PE2001000826 A PE 2001000826A PE 20020323 A1 PE20020323 A1 PE 20020323A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitors
- ace
- pharmaceutical composition
- insulin secretion
- hmg
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 102000015427 Angiotensins Human genes 0.000 title abstract 2
- 108010064733 Angiotensins Proteins 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 239000003623 enhancer Substances 0.000 title abstract 2
- 230000003914 insulin secretion Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108010061435 Enalapril Proteins 0.000 abstract 2
- -1 GLYCOPYRAMIDE Chemical compound 0.000 abstract 2
- 229960000830 captopril Drugs 0.000 abstract 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 2
- 229960000873 enalapril Drugs 0.000 abstract 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 abstract 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 abstract 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 abstract 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001466 acetohexamide Drugs 0.000 abstract 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 abstract 1
- 229950007884 alacepril Drugs 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 229960004530 benazepril Drugs 0.000 abstract 1
- 229960005110 cerivastatin Drugs 0.000 abstract 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 abstract 1
- 229960001761 chlorpropamide Drugs 0.000 abstract 1
- 229960003765 fluvastatin Drugs 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960002797 pitavastatin Drugs 0.000 abstract 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 abstract 1
- 229960002277 tolazamide Drugs 0.000 abstract 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 abstract 1
- 229960005371 tolbutamide Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN POTENCIADOR DE LA SECRESION DE INSULINA TAL COMO TOLBUTAMIDA, CLORPROPAMIDA, TOLAZAMIDA, ACETOHEXAMIDA, GLICOPIRAMIDA, GLIBENCLAMIDA, GLIMEPIRIDA, NATEGLINIDA, ENTRE OTROS Y b) INHIBIDORES DE HMG-Co-A-REDUCTASA SELECCIONADO DE ATORVASTATINA, CERIVASTATINA, FLUVASTATINA, LOVASTATINA, PITAVASTATINA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) SELECCIONADOS DE ALACEPRIL, BENAZEPRIL, ENALAPRIL, CAPTOPRIL, DELAPRIL, RAMIPRIL, QUINAPRIL, ENTRE OTROS. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE HIPERGLICEMIA, HIPERINSULINEMIA, HIPERLIPIDEMIA, RESISTENCIA A LA INSULINA, RETINOPATIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64364200A | 2000-08-22 | 2000-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020323A1 true PE20020323A1 (es) | 2002-06-13 |
Family
ID=24581693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000826A PE20020323A1 (es) | 2000-08-22 | 2001-08-17 | COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20040087630A1 (es) |
| EP (1) | EP1359907A2 (es) |
| JP (1) | JP2004519424A (es) |
| AR (1) | AR030379A1 (es) |
| AU (1) | AU2002214952A1 (es) |
| PE (1) | PE20020323A1 (es) |
| TW (1) | TW200833321A (es) |
| WO (1) | WO2002015892A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60216453T2 (de) * | 2001-06-20 | 2007-09-20 | Merck Santé | Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels |
| US20030171407A1 (en) * | 2002-03-07 | 2003-09-11 | Upsher-Smith Laboratories, Inc. | Composition for reducing blood glucose and cholesterol |
| TW200304813A (en) * | 2002-03-11 | 2003-10-16 | Novartis Ag | Salts of organic acid |
| TW200810743A (en) * | 2002-03-22 | 2008-03-01 | Novartis Ag | Combination of organic compounds |
| GB0217306D0 (en) * | 2002-07-25 | 2002-09-04 | Novartis Ag | Compositions comprising organic compounds |
| US20070161700A1 (en) * | 2004-12-28 | 2007-07-12 | Kowa Company, Ltd. | Inhibitor for the formation of y-secretase complex |
| JP4955392B2 (ja) * | 2004-07-01 | 2012-06-20 | キッセイ薬品工業株式会社 | 血管内膜過増殖疾患の予防または治療剤 |
| US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| KR101436644B1 (ko) * | 2006-01-31 | 2014-09-01 | 코와 가부시키가이샤 | 당뇨병 치료제 |
| US8685952B2 (en) | 2006-01-31 | 2014-04-01 | Kowa Co., Ltd. | Method for the treatment of diabetes |
| EP2779999A2 (en) | 2011-11-15 | 2014-09-24 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising atorvastatin and glimepiride |
| US11446236B2 (en) | 2015-08-05 | 2022-09-20 | Cmpd Licensing, Llc | Topical antimicrobial compositions and methods of formulating the same |
| US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US12502370B2 (en) * | 2019-04-11 | 2025-12-23 | Cmpd Licensing, Llc | Wound treatments and compositions |
| US12156875B2 (en) | 2019-04-11 | 2024-12-03 | Cmpd Licensing, Llc | Wound treatments and compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998027974A1 (en) * | 1996-12-23 | 1998-07-02 | Merck & Co., Inc. | Antidiabetic agents |
| GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| TWI260321B (en) * | 1999-09-22 | 2006-08-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| JP2003518130A (ja) * | 1999-12-22 | 2003-06-03 | メルク フロスト カナダ アンド カンパニー | 蛋白チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）阻害薬としてのホスホン酸誘導体 |
| DE60128475T2 (de) * | 2000-07-25 | 2008-02-07 | Merck & Co., Inc. | N-substituierte indole mit anwendung in der behandlung von diabetes |
| CA2437118A1 (en) * | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
-
2001
- 2001-08-17 PE PE2001000826A patent/PE20020323A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103949A patent/AR030379A1/es unknown
- 2001-08-20 JP JP2002520813A patent/JP2004519424A/ja not_active Withdrawn
- 2001-08-20 AU AU2002214952A patent/AU2002214952A1/en not_active Abandoned
- 2001-08-20 TW TW097116517A patent/TW200833321A/zh unknown
- 2001-08-20 EP EP01983442A patent/EP1359907A2/en not_active Withdrawn
- 2001-08-20 US US10/362,341 patent/US20040087630A1/en not_active Abandoned
- 2001-08-20 WO PCT/EP2001/009586 patent/WO2002015892A2/en not_active Ceased
-
2008
- 2008-10-27 US US12/290,106 patent/US20090131404A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR030379A1 (es) | 2003-08-20 |
| AU2002214952A1 (en) | 2002-03-04 |
| US20090131404A1 (en) | 2009-05-21 |
| EP1359907A2 (en) | 2003-11-12 |
| TW200833321A (en) | 2008-08-16 |
| US20040087630A1 (en) | 2004-05-06 |
| WO2002015892A2 (en) | 2002-02-28 |
| WO2002015892A3 (en) | 2003-09-04 |
| JP2004519424A (ja) | 2004-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020323A1 (es) | COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) | |
| TR200102229T2 (tr) | 3-Hidroksi-2-metilglutaril koenzim A redüktaz inhibitörlerinin diyabetik retinopati tedavisine yönelik bir ilacın imalatında kullanımı. | |
| DE60022525D1 (de) | Ramipril zur vorbeugung von kardiovaskulären vorfällen | |
| WO1998046588A3 (en) | Compounds and therapies for the prevention of vascular and non-vascular pathologies | |
| EP1559424A3 (en) | The use of inhibitors of the renin-angiotensin system | |
| CA2461958A1 (en) | Combination dosage form containing a cholesterol-lowering agent, a renin-angiotensin inhibitor, and aspirin | |
| PE20040291A1 (es) | COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA | |
| PE106999A1 (es) | Composicion de amlodipina y una estatina | |
| CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
| WO2005077103A3 (en) | Compositions and methods for modification and prevention of sars coronavirus infectivity | |
| AR015504A1 (es) | COMPOSICION FARMACEUTICA QUE COMPRENDE UNA CANTIDAD EFECTIVA DE UN INHIBIDOR DE ENZIMA CONVERSORA DE ANGIOTENSINA Y UNA CANTIDAD EFECTIVA DE UN INHIBIDORDE METALOPROTEINASA DE MATRIZ Y USO DE DICHOS COMPUESTOS PARA PREPARAR DICHA COMPOSICIoN FARMACEUTICA. | |
| EP1072273A4 (en) | VASKULARISIERUNGSINHIBITOREN | |
| TW200637546A (en) | Combination therapy | |
| MY118381A (en) | Statin-carboxyalkylether combinations | |
| NO20000045D0 (no) | Farmasoeytiske blandinger omfattende en aldosereduktase- inhibitor og en ace-inhibitor | |
| ES2129563T3 (es) | Empleo de una combinacion de un inhibidor de la enzima convertidora de angiotensina y un antagonista del calcio para el tratamiento de una proteinuria. | |
| AR043016A2 (es) | Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene | |
| ATE340567T1 (de) | Transdermales therapeutisches system zur verabreichung des partiellen dopamin-d2-agonisten aripiprazol | |
| UY26218A1 (es) | Combinacion de inhibidores de mtp e inhibidores de hmg- coa reductasa y su uso en medicamentos. ley 17.164.- | |
| MXPA02004021A (es) | Mezcla terapeutica de inhibidores de hmg-coa reductasa. | |
| DK1240901T3 (da) | Medicinske præparater til behandling og forebyggelse af sygdomme baseret på abnorm blodkoagulation | |
| AU1662300A (en) | Agent for lowering endothelin levels | |
| AR025576A1 (es) | Preparacion farmaceutica para hipertension arterial | |
| DE60112117D1 (de) | Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril | |
| WO2006030030A3 (de) | System zur sequentiellen, transdermalen verabreichung von systemisch wirksamen substanzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |